title: Fluticasone furoate/vilanterol: a review of its use in patients with asthma.
abstract: Fluticasone furoate/vilanterol (Relvar(®)) is a once-daily, fixed combination of an inhaled corticosteroid (ICS) and a long-acting β2-adrenoreceptor agonist (LABA), delivered via a dry powder inhaler (Ellipta(®)). It is approved for the treatment of asthma in the EU and Japan, and is the first once-daily ICS/LABA to be available for this indication. Fluticasone furoate is an enhanced-affinity glucocorticoid receptor agonist, with potent anti-inflammatory activity. Vilanterol produces rapid and prolonged bronchodilation. In phase III trials in adolescents and adults with various levels of asthma uncontrolled on ICS and/or ICS/LABA, fluticasone furoate/vilanterol 100/25 or 200/25 µg once daily (approved dosages in the EU) significantly improved pulmonary function compared with placebo or equivalent dosages of fluticasone furoate alone (in some trials) or fluticasone propionate. In similar trials, fluticasone furoate/vilanterol 100/25 µg once daily was as effective as fluticasone propionate/salmeterol 250/50 µg twice daily in improving pulmonary function and significantly reduced the risk of severe asthma exacerbation relative to fluticasone furoate alone. In clinical trials, fluticasone furoate/vilanterol was generally well tolerated with fewer than 15 % of patients experiencing treatment-related adverse events, the most common of which were oral/oropharyngeal candidiasis, dysphonia, extrasystoles and cough. The tolerability profile of fluticasone furoate/vilanterol was generally similar to that of fluticasone propionate/salmeterol. Thus, fluticasone furoate/vilanterol is an effective and generally well tolerated ICS/LABA option for the treatment of uncontrolled asthma.
authors: Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand, demail@springer.com.
authors: Yahiya Y
authors: YY
authors: Syed
mesh_terms: D000280:Administration, Inhalation; D000730:Androstadienes / Q000008:administration & dosage* / Q000378:metabolism; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000378:metabolism; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D001592:Benzyl Alcohols / Q000008:administration & dosage* / Q000378:metabolism; D002722:Chlorobenzenes / Q000008:administration & dosage* / Q000378:metabolism; D004359:Drug Therapy, Combination; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000379:methods
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D001592:Benzyl Alcohols; D002722:Chlorobenzenes; C550468:vilanterol; C523187:fluticasone furoate
references: Clin Transl Allergy. 2012 Jun 27;2(1):11
references: 22738148
references: Br J Clin Pharmacol. 2014 Mar;77(3):466-79
references: 24093504
references: Thorax. 2014 Dec;69(12):1152-4
references: 24603195
references: Eur Respir J. 2012 Sep;40(3):570-9
references: 22362859
references: Eur Respir J. 2014 Mar;43(3):773-82
references: 24136330
references: Mol Pharmacol. 2008 Jan;73(1):203-14
references: 17901197
references: J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):553-61
references: 25213048
references: Drug Metab Dispos. 2013 Jan;41(1):89-100
references: 23043183
references: Drug Metab Dispos. 2008 Nov;36(11):2337-44
references: 18694910
references: Eur J Pharmacol. 2011 Nov 16;670(1):244-51
references: 21920359
references: Br J Clin Pharmacol. 2014 May;77(5):808-20
references: 24152086
references: Thorax. 2013 Jun;68(6):513-20
references: 23440247
references: BMC Pulm Med. 2013 Dec 07;13:72
references: 24314123
references: Ann Allergy Asthma Immunol. 2012 Nov;109(5):353-358.e4
references: 23062392
references: Pulm Pharmacol Ther. 2013 Apr;26(2):256-64
references: 23232038
references: Respir Res. 2011 Dec 21;12:160
references: 22188590
references: Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L660-7
references: 17575011
references: Br J Clin Pharmacol. 2013 Jun;75(6):1478-87
references: 23116485
references: Respir Med. 2012 May;106(5):642-50
references: 22342538
references: Clin Pharmacokinet. 2013 Jan;52(1):37-42
references: 23184737
references: Drugs. 2014 Sep;74(13):1509-22
references: 25074268
references: Thorax. 2014 Apr;69(4):312-9
references: 24253831
references: Respir Res. 2007 Jul 25;8:54
references: 17650349
references: J Med Chem. 2008 Jun 26;51(12):3349-52
references: 18522385
references: Clin Respir J. 2013 Oct;7(4):397-406
references: 23578031
references: J Manag Care Pharm. 2012 Sep;18(7):527-39
references: 22971206
references: Pharmacol Rev. 2012 Jul;64(3):450-504
references: 22611179
references: PLoS One. 2014 Apr 07;9(4):e93754
references: 24710117
references: Thorax. 2012 Jan;67(1):35-41
references: 21828231
references: Respir Med. 2013 Dec;107(12):1873-80
references: 24200619
references: Allergy. 2013 Sep;68(9):1136-42
references: 23924233
references: Respir Med. 2012 Aug;106(8):1110-5
references: 22520084
references: Chest. 2013 Oct;144(4):1222-1229
references: 23846316
references: J Pharmacol Exp Ther. 2013 Jan;344(1):218-30
references: 23131596
references: Clin Ther. 2012 Dec;34(12):2316-32
references: 23200625